Government to speed up access to new cancer drugs
April 24, 2012Sales and Marketing CDF, Cancer, Roche, UK, avastin, government, sha
Access to England’s Cancer Drugs Fund will be speeded up, ministers have confirmed. Currently, it can take a number of …
Mylan earmarks €380m for Irish expansion
April 24, 2012Manufacturing and Production Galway, Ireland, Mylan, manufacturing and production
Generic drugmaker Mylan has announced a plan to invest €380 million in its operations in the Republic of Ireland, including …
Baxter planning $1 billion plasma facility for Atlanta
April 24, 2012Manufacturing and Production Atlanta, baxter, manufacturing, production
Baxter International has unveiled plans to build a major new manufacturing complex for its plasma-based therapies in Atlanta in the …
Falsified Medicines Directive in the EU
April 23, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Dated 16 April 2012, the European Commission has issued the Draft Template for the Written Confirmation for Active Substances Imported …
GMC to create guidance on doctors’ use of social media
April 23, 2012Medical Communications BMA, Facebook, GMC, Twitter, social media
The General Medical Council is creating new draft guidance about what it expects from doctors when they are using social …
Abbott launches online tool for ankylosing spondylitis
April 23, 2012Medical Communications AS, Abbott, NHS, NICE, ankylosing spondylitis
Abbott has launched a new online assessment tool that has the potential to change the landscape of ankylosing spondylitis (AS) …
Pfizer sells nutrition business to Nestlé for $11.9 billion
April 23, 2012Business Services, Sales and Marketing Business, Lipitor, Pfizer, nestle, nutrition
Pfizer has sold its nutrition business to Nestlé for $11.85 billion in cash. Pfizer Nutrition is a leading global pediatric …
AstraZeneca diabetes drug recommended in Europe
April 23, 2012Sales and Marketing AstraZeneca, CHMP, FDA, Merck, WHO, diabetes
AstraZeneca and Bristol-Myers Squibb’s new type II diabetes treatment Forxiga has received a positive opinion by European regulators. The European …
AstraZeneca to buy Ardea for $1.3 billion
April 23, 2012Research and Development, Sales and Marketing Ardea, AstraZeneca, febuxostat, gout
AstraZeneca is to buy Ardea Biosciences for $1 billion to help bolster its pipeline. Under the terms of the agreement, …
Petition launched to raise AF and stroke awareness
April 20, 2012Business Services, Medical Communications, Sales and Marketing AF, Boehringer Ingelheim, Pradaxa, Xarelto, stroke
Various health organisations have called on more people involved in the management of atrial fibrillation (AF) to help raise awareness …
New safety warnings recommended for Gilenya
April 20, 2012Medical Communications, Sales and Marketing EMA, Novartis, gilenya
A safety review of Novartis’ MS treatment Gilenya has concluded the drug should stay on the market, but that patients …
1 in 3 surveyed says social media changes attitudes to medicines
April 20, 2012Business Services, Medical Communications, Sales and Marketing Facebook, Twitter, digital, pwC, social networking
A third of US social media users say it could change the way they think about their medicines, according to …
Hanson Zandi appoints two new directors
April 20, 2012Business Services, Medical Communications, Sales and Marketing Hanson Zandi, health comms
Healthcare comms agency Hanson Zandi has made two new appointments with Damion Hampton and Will Elliott. Hampton joins as account …
Sylva Michelli joins Pegasus as associate director
April 20, 2012Business Services, Medical Communications, Sales and Marketing Pegasus PR, Pegasus PR. Sylva Michelli, Sylva Michelli
Healthcare comms specialist Pegasus has appointed Sylva Michelli as associate director to strengthen the agency’s pharmaceutical and life sciences division. …
Kantar Health appoints Richard Goosey as UK senior director
April 20, 2012Business Services, Medical Communications, Sales and Marketing Kantar Health, Richard Goosey, Roche
Consultancy and marketing insights company Kantar Health has appointed Richard Goosey as UK senior director of Advanced Methods. Goosey has …
EMA request feedback on the draft EU reference dates
April 19, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wainwright Associates; EMA; Pharmacovigilance; PV
The European Medicines Agency has invited marketing-authorisation holders and other stakeholders to review and provide comments on the draft list …
GSK’s bid for Human Genome Sciences rejected
April 19, 2012Sales and Marketing Benlysta, GSK, Human Genome Sciences, mergers and acquisitions
GlaxoSmithKline has launched a takeover bid for Human Genome Sciences for around $2.5 billion, but has been rejected by the …
Pharma R&D downsizing hits academic researchers
April 19, 2012Research and Development ABPI, academic alliance, academic research
A survey of pharma’s research partnerships and funding of UK academics has raised concerns about the future of British science.The …
Roche abandons Illumina takeover bid
April 19, 2012Sales and Marketing Diagnostics, Illumina, Roche, mergers and acquisitions
Roche has conceded defeat in its bid to buy Illumina, after shareholders of the diagnostics firm blocked the takeover – …
Kantar Health Names Goosey Senior Director, Advanced Methods in UK
April 18, 2012Business Services Kantar Health, Richard Goosey, clinical statistics, market research
NEW YORK, April 18, 2012—Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, has named Richard Goosey Senior …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
